|
gptkbp:instance_of
|
gptkb:diabetes
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:class
|
gptkb:diabetes
antidiabetic agent
|
|
gptkbp:clinical_trial
|
Phase 3
NCT01234567
NCT01234568
NCT01234569
NCT01234570
NCT01234571
|
|
gptkbp:clinical_use
|
blood glucose control
|
|
gptkbp:contraindication
|
hypersensitivity to insulin glargine
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
gptkb:beer
gptkb:ACE_inhibitors
beta-blockers
thiazolidinediones
|
|
gptkbp:duration
|
24 hours
|
|
gptkbp:effective_date
|
2015-12-15
|
|
gptkbp:form
|
injection
|
|
gptkbp:formulation
|
injectable solution
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Basaglar
|
|
gptkbp:indication
|
gptkb:Type_1_diabetes
Type 2 diabetes
|
|
gptkbp:ingredients
|
gptkb:insulin_glargine
|
|
gptkbp:invention
|
2024-12-31
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
insulin receptor agonist
|
|
gptkbp:packaging
|
pre-filled pen
|
|
gptkbp:patient_education
|
proper injection technique
monitor blood glucose levels
recognize hypoglycemia symptoms
diet and exercise importance
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
long-acting insulin
|
|
gptkbp:provides_guidance_on
|
gptkb:diabetes
gptkb:European_Association_for_the_Study_of_Diabetes
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:related_products
|
gptkb:Lantus
gptkb:Toujeo
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:shelf_life
|
28 days after opening
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
allergic reactions
weight gain
injection site reactions
hypoglycemia
edema
|
|
gptkbp:used_for
|
gptkb:diabetes
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly
|
|
gptkbp:bfsLayer
|
4
|